Investigation of Safety, Tolerability and Pharmacokinetic Properties of Single Subcutaneous Doses of NNC0194-0499 in Japanese and Non-Asian Male Subjects
Latest Information Update: 04 May 2021
At a glance
- Drugs NNC0194 0499 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 29 Apr 2021 Status changed from active, no longer recruiting to completed.
- 13 Apr 2021 Status changed from recruiting to active, no longer recruiting.
- 26 Feb 2021 Status changed from not yet recruiting to recruiting.